Vera Therapeutics, Inc.
VERA
$34.26
-$1.02-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 138.81% | 145.80% | 124.17% | 189.44% | 173.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.37% | 118.79% | 92.60% | 68.53% | 114.61% |
| Operating Income | -40.37% | -118.79% | -92.60% | -68.53% | -114.61% |
| Income Before Tax | -43.04% | -134.13% | -109.78% | -72.18% | -127.04% |
| Income Tax Expenses | -- | -- | 0.00% | -- | -- |
| Earnings from Continuing Operations | -43.04% | -134.13% | -109.78% | -72.18% | -127.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.04% | -134.13% | -109.78% | -72.18% | -127.04% |
| EBIT | -40.37% | -118.79% | -92.60% | -68.53% | -114.61% |
| EBITDA | -40.41% | -118.87% | -92.54% | -68.36% | -114.38% |
| EPS Basic | -27.02% | -108.56% | -94.00% | -48.06% | -94.79% |
| Normalized Basic EPS | -27.02% | -107.88% | -93.58% | -48.05% | -94.80% |
| EPS Diluted | -27.02% | -108.56% | -94.00% | -48.06% | -94.79% |
| Normalized Diluted EPS | -27.02% | -107.88% | -93.58% | -48.05% | -94.80% |
| Average Basic Shares Outstanding | 12.62% | 12.26% | 8.13% | 16.30% | 16.56% |
| Average Diluted Shares Outstanding | 12.62% | 12.26% | 8.13% | 16.30% | 16.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |